Positive results from early trial of drug that could protect brain cells
Date
News
Date
The earlier groundbreaking clinical trial proved inconclusive. So we’re launching a new company tasked with planning a possible new trial.
Date
The broadcasting legend will front a new 6-part jazz series, which will also highlight the work of Parkinson’s UK.
Date
New research has advanced our understanding of a protein called alpha-synuclein, which is believed to play a central role in damaging brain cells in Parkinson’s.
Date
As Steve Ford prepares to step down, Shān brings extensive leadership experience from across the charity sector to Parkinson’s UK.
Date
Scientists in the UK have uncovered evidence that simple vision tests can predict who will develop Parkinson's dementia. And the evidence shows that a loss of wiring in the brain may be the cause.
Date
We’ve partnered with Alzheimer’s Society and University College London Hospitals (UCLH) Biomedical Research Centre. Together, we’ve developed a new resource to help lab-based researchers with patient and public involvement (PPI).
Date
Parkinson's didn't stop for coronavirus, and neither did we. Here are the three things we’re most proud of this year, and how you can get involved in 2021.
Date
Our 2020 volunteer award winners have been announced
Date
Our recent survey has found that nearly three quarters (74%) of people on Parkinson's medication experience 'wearing off', when symptoms including pain, stiffness and tremors become worse between doses.
Date
Parkinson’s UK is joining forces with US charity The Michael J. Fox Foundation and biopharma company Neurolixis to fund a £1.5m clinical trial of an exciting new drug to combat dyskinesia in people with Parkinson’s.